featured – Page 13 – pharmaceutical daily

December 22, 2015 Off

Janssen and Bavarian Nordic to develop vaccine for Chronic Human Papillomavirus (HPV) infections

Janssen Pharmaceuticals, Inc. (Janssen) has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.

December 21, 2015 Off

Martin Shkreli attributes arrest to drug-price hikes – WSJ

By Dino Mustafić

Martin Shkreli, the pharmaceutical entrepreneur facing U.S. charges of securities fraud, has said he had been the target of legal authorities for his much-criticized drug-price hikes and his over-the-top public persona

December 17, 2015 Off

Bristol’s drug pricing under fire as UK agency rejects Opdivo

By Dino Mustafić

Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.

December 17, 2015 Off

Lilly’s and Boehringer Ingelheim’s insuline injection gets FDA’s nod

By Dino Mustafić

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) were granted approval by the U.S. Food and Drug Administration (FDA) for Basaglar (insulin glargine injection) 100 units/mL.

December 16, 2015 Off

AstraZeneca divests Entocort US rights to Perrigo for $380M

By Dino Mustafić

AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.

December 16, 2015 Off

Lilly welcomes new board member

By Dino Mustafić

Eli Lilly and Company has elected Juan R. Luciano as a new member of its board, effective February 1, 2016.

December 14, 2015 Off

AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion – WSJ

By Dino Mustafić

British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).

December 14, 2015 Off

Horizon buys Crealta Holdings for $510M

By Dino Mustafić

Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.

December 14, 2015 Off

Alvogen to market Natco’s generic Tamiflu capsules until 2017

By Dino Mustafić

Alvogen to market Natco’s generic Tamiflu capsules until 2017.

December 10, 2015 Off

Rhizen and Novartis enter deal for PI3K delta gamma inhibitor

By Dino Mustafić

Rhizen Pharmaceuticals has entered into an exclusive, worldwide agreement with Novartis for the development and commercialization of Rhizen’s inhaled dual PI3K-delta gamma inhibitor and its closely related compound for various indications.